TIL therapy for advanced solid tumors
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that can be surgically removed to make the TIL therapy.
- You should be between 18 and 75 years old.
- You have tried standard treatments and they no longer work, but you are still healthy enough to try this therapy (ECOG score 0-1).
- You must have at least one tumor that can be measured on scans.
- You cannot have other active cancers, serious heart problems, or active infections like HIV, hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.